A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

NCT00660283 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Glioma

Interventions

DRUG: Temozolomide

Sponsor

Kentuckiana Cancer Institute

Collaborators

[object Object]